GleamWall
中文EN

APTN ADAPTIN BIO, INC.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1938571 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-0.4%
TTM EPS YoY30.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-452.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets253.9%
Debt / equity—
Current ratio0.39x
Interest coverage-485.91x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$115,956$138,167$165,577$593,035$778,664$340,334$62,133$258,058
SG&A expense$838,419$1.06M$978,576$774,983$896,948$1.18M$788,325$250,022
Operating income-$954,375-$1.20M-$1.14M-$1.37M-$1.68M-$1.52M-$850,458$1.91M
Interest expense$2,966$4,696$1,943$0$0$0$72,659-$189,375
Pretax income-$957,341-$1.21M-$1.15M-$1.37M-$1.68M-$1.52M-$603,084-$856,836
Net income-$957,341-$1.21M-$1.15M-$1.37M-$1.68M-$1.52M-$603,084-$856,836
EPS (basic)-0.10-0.14-0.13—-0.20-0.18-0.10—
EPS (diluted)-0.10-0.140.13—-0.20-0.180.10—
Weighted avg. shares (diluted)9.21M8.85M8.70M—8.46M8.45M5.83M—
Balance sheet
Cash & equivalents$430,333$670,488$301,309$459,174$579,089$1.35M$2.37M$34,085
Current assets$1.09M$981,452$706,117$619,159$979,474$1.66M$2.85M$45,539
Total assets$1.09M$981,452$706,117$619,159$979,474$1.66M$2.85M$239,415
Current liabilities$2.76M$2.65M$2.48M$2.11M$1.86M$1.19M$1.11M$4.34M
Total liabilities$2.76M$2.65M$2.48M$2.11M$1.86M$1.19M$1.11M$4.34M
Shareholders' equity-$1.67M-$1.67M-$1.78M-$1.49M-$881,078$474,409$1.75M-$4.10M
Shares outstanding9.26M9.05M8.79M8.66M8.46M8.46M8.40M3.25M
Cash flow statement
Operating cash flow-$964,551-$450,164-$596,298-$702,876-$772,430-$1.02M-$2.28M$112,653
Financing cash flow$724,396$819,343$438,433$582,961$0$0$4.62M-$193,876
Stock-based compensation$184,359$193,806$345,396$176,739$320,125———

Free plan shows the latest 8 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.